Skip to main content
. 2019 May 30;5:16. doi: 10.1038/s41523-019-0111-0

Fig. 2.

Fig. 2

SETER/PR and patient survival. SETER/PR and progression-free and overall survival in patients with HR+/HER2 metastatic breast cancer. Kaplan−Meier curves are shown for progression-free a and overall survival b in patients that presented with relapsed stage IV breast cancer and received endocrine therapy as next treatment and for the clinically relevant subgroup of patients with a prior history of sensitivity to adjuvant or metastatic endocrine treatment c, d